反应详情

2-(5-Chloro-3-methyl-1H-indazol-1-yl)-N-(1-hydroxy-2-methylpropan-2-yl)-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide (80 mg, 151 μmol) was dissolved in dichloromethane (2 mL) and trifluoroacetic acid (1 mL) added. After stirring for 15 h the mixture was concentrated in vacuo, a Jan. 10, 1960 mixture of ammonium hydroxide/methanol/dichloromethane (25 mL) added, and the mixture stirred for 1 h then concentrated in vacuo. Purification by chromatography (silica, 24 g Analogix column, 0-4% methanol containing 10% ammonium hydroxide in dichloromethane) gave 2-(5-chloro-3-methyl-indazol-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (2hydroxy-1,1-dimethyl-ethyl)-amide (46.8 mg 77%) as a solid. MS (M−H)−=397; 1H NMR (DMSO-d6) δ: 8.99 (s, 1H), 8.65 (d, J=9.0 Hz, 1H), 8.39 (d, J=2.6 Hz, 1H), 8.05 (d, J=1.5 Hz, 1H), 7.59-7.62 (m, 1H), 7.58 (d, J=2.1 Hz, 1H), 3.59 (d, J=5.7 Hz, 2H), 2.64 (s, 3H), 1.44 (s, 6H).

1. concentrationwas concentrated in vacuo
2. addition10, 1960 mixture of ammonium hydroxide/methanol/dichloromethane (25 mL)
3. additionadded
4. stirringthe mixture stirred for 1 h
5. concentrationthen concentrated in vacuo
6. customPurification by chromatography (silica, 24 g Analogix column, 0-4% methanol containing 10% ammonium hydroxide in dichloromethane)